Optimization of post‐remission therapies to maintain complete remission and prevent
relapse is a major challenge in treating patients with acute myeloid leukemia (AML) …

The treatment of acute myeloid leukemia (AML) has evolved over the past few years with the
advent of next-generation sequencing. Targeted therapies alone or in combination with low …

The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed
adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence …

Relapse in acute myeloid leukemia (AML) is common, especially in older patients, and there
is currently no standard of care maintenance therapy for those who achieve complete …

Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic
syndrome (MDS). However, only around 50% of patients respond to these agents, and …

Recent studies have provided several insights into acute myeloid leukemia. Studies based
on molecular biology have identified eight functional mutations involved in leukemogenesis …

Patients with relapsed and refractory acute myeloid leukemia (RR AML), especially those in
non-remission (NR) have a poor prognosis after allogeneic hematopoietic stem cell …

Allo-HSCT remains the standard of care for high-risk AML. Increased access to transplant,
reduced toxicity and relapse are improving patient outcomes. Further research is needed to …

Azacitidine (AZA) maintenance following allogeneic hematopoietic cell transplantation
(HCT) for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) may reduce …

Myelodysplastic syndromes (MDS) represent a group of clonal myeloid neoplasms with a
high degree of variability in regards to their clinical phenotype, prognosis, and response to …